Pharmacokinetics and Pharmacogenetics of Dabigatran
Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists. However, pharmacokinetics and pharmacogenetics of dabigatran are variable. This can affect both effectiveness and sa...
Saved in:
| Main Authors: | A. V. Savinova, V. S. Dobrodeeva, M. M. Petrova, R. F. Nasyrova, N. A. Shnayder |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2021-03-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2400 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics and bioequivalence of the generic and original dabigatran etexilate after a single dose in healthy volunteers
by: V. B. Vasilyuk, et al.
Published: (2024-10-01) -
UGT2B15 single nucleotide polymorphism reduces dabigatran acylglucuronide formation in humans
by: Jin-Woo Park, et al.
Published: (2025-01-01) -
Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01) -
IMPACT OF ABCB1 AND CES1 GENETIC POLYMORPHISMS ON TROUGH STEADY-STATE DABIGATRAN CONCENTRATIONS IN PATIENTS AFTER ENDOPROSTHESIS OF KNIFE JOIN
by: D. A. Sychev, et al.
Published: (2018-05-01) -
Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020-11-01)